Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration
Abstract Purpose To detect immunoglobulins in aqueous humour of AMD patients after repeated administration of intravitreal aflibercept. Patients and methods Twenty-one patients (age: 77.85 ± 9.21 years) previously treated with intravitreal aflibercept due to wet type age-related macular degeneration...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-01-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12886-022-02761-9 |
| _version_ | 1797952659452329984 |
|---|---|
| author | Andrea Gyenes Lilla István Fruzsina Benyó András Papp Miklós Resch Noémi Sándor Mihály Józsi Zoltán Z. Nagy Illés Kovács Szilárd Kiss |
| author_facet | Andrea Gyenes Lilla István Fruzsina Benyó András Papp Miklós Resch Noémi Sándor Mihály Józsi Zoltán Z. Nagy Illés Kovács Szilárd Kiss |
| author_sort | Andrea Gyenes |
| collection | DOAJ |
| description | Abstract Purpose To detect immunoglobulins in aqueous humour of AMD patients after repeated administration of intravitreal aflibercept. Patients and methods Twenty-one patients (age: 77.85 ± 9.21 years) previously treated with intravitreal aflibercept due to wet type age-related macular degeneration (AMD group) and 18 age-matched control subjects (age: 69.75 ± 12.67 years) were included in this study. Patients in the AMD group received a mean of 5 intravitreal injections (min: 1 max: 17) prior to the cataract surgery. Samples of aqueous humour (50 μl) were obtained by anterior chamber paracentesis as the first step of routine cataract surgery. The IgG content of the samples was analysed by an in-house developed ELISA system. Results A significant increase in nonspecific IgG levels in the AMD group was detected compared to the control group (13.37 ± 6.65 vs. 9.44 ± 6.55 μg/ml; p = 0.03). In 11 patients, intraocular anti-aflibercept immunoglobulins could be detected (0.05 ± 0.01 μg/ml) which was significantly higher than the limit of detection for anti-aflibercept (0.04 μg/ml; p = 0.001). No correlation was found between the number of injections or the type of CNV and the aqueous level of anti-aflibercept (r = 0.02; p = 0.95). Conclusion According to our results, penetration of non-specific systemic antibodies through the impaired blood-retinal barrier is higher in patients with neovascular AMD than in subjects with an intact structural barrier. Evaluation of neutralizing antibodies to anti-VEGF agents in the aqueous humour can lead us to understanding tachyphylaxis and changes in intraocular immune mechanisms due to AMD. |
| first_indexed | 2024-04-10T22:49:55Z |
| format | Article |
| id | doaj.art-edcbce9992864a83a52ec05b3dd6dea6 |
| institution | Directory Open Access Journal |
| issn | 1471-2415 |
| language | English |
| last_indexed | 2024-04-10T22:49:55Z |
| publishDate | 2023-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj.art-edcbce9992864a83a52ec05b3dd6dea62023-01-15T12:07:14ZengBMCBMC Ophthalmology1471-24152023-01-012311810.1186/s12886-022-02761-9Intraocular neutralizing antibodies against aflibercept in patients with age related macular degenerationAndrea Gyenes0Lilla István1Fruzsina Benyó2András Papp3Miklós Resch4Noémi Sándor5Mihály Józsi6Zoltán Z. Nagy7Illés Kovács8Szilárd Kiss9Department of Ophthalmology, Semmelweis UniversityDepartment of Ophthalmology, Semmelweis UniversityDepartment of Ophthalmology, Semmelweis UniversityDepartment of Ophthalmology, Semmelweis UniversityDepartment of Ophthalmology, Semmelweis UniversityDepartment of Immunology, ELTE Eötvös Loránd UniversityDepartment of Immunology, ELTE Eötvös Loránd UniversityDepartment of Ophthalmology, Semmelweis UniversityDepartment of Ophthalmology, Semmelweis UniversityDepartment of Ophthalmology, Weill Cornell Medical CollegeAbstract Purpose To detect immunoglobulins in aqueous humour of AMD patients after repeated administration of intravitreal aflibercept. Patients and methods Twenty-one patients (age: 77.85 ± 9.21 years) previously treated with intravitreal aflibercept due to wet type age-related macular degeneration (AMD group) and 18 age-matched control subjects (age: 69.75 ± 12.67 years) were included in this study. Patients in the AMD group received a mean of 5 intravitreal injections (min: 1 max: 17) prior to the cataract surgery. Samples of aqueous humour (50 μl) were obtained by anterior chamber paracentesis as the first step of routine cataract surgery. The IgG content of the samples was analysed by an in-house developed ELISA system. Results A significant increase in nonspecific IgG levels in the AMD group was detected compared to the control group (13.37 ± 6.65 vs. 9.44 ± 6.55 μg/ml; p = 0.03). In 11 patients, intraocular anti-aflibercept immunoglobulins could be detected (0.05 ± 0.01 μg/ml) which was significantly higher than the limit of detection for anti-aflibercept (0.04 μg/ml; p = 0.001). No correlation was found between the number of injections or the type of CNV and the aqueous level of anti-aflibercept (r = 0.02; p = 0.95). Conclusion According to our results, penetration of non-specific systemic antibodies through the impaired blood-retinal barrier is higher in patients with neovascular AMD than in subjects with an intact structural barrier. Evaluation of neutralizing antibodies to anti-VEGF agents in the aqueous humour can lead us to understanding tachyphylaxis and changes in intraocular immune mechanisms due to AMD.https://doi.org/10.1186/s12886-022-02761-9Age related macular degenerationanti-VEGFTreatment |
| spellingShingle | Andrea Gyenes Lilla István Fruzsina Benyó András Papp Miklós Resch Noémi Sándor Mihály Józsi Zoltán Z. Nagy Illés Kovács Szilárd Kiss Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration BMC Ophthalmology Age related macular degeneration anti-VEGF Treatment |
| title | Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration |
| title_full | Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration |
| title_fullStr | Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration |
| title_full_unstemmed | Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration |
| title_short | Intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration |
| title_sort | intraocular neutralizing antibodies against aflibercept in patients with age related macular degeneration |
| topic | Age related macular degeneration anti-VEGF Treatment |
| url | https://doi.org/10.1186/s12886-022-02761-9 |
| work_keys_str_mv | AT andreagyenes intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration AT lillaistvan intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration AT fruzsinabenyo intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration AT andraspapp intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration AT miklosresch intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration AT noemisandor intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration AT mihalyjozsi intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration AT zoltanznagy intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration AT illeskovacs intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration AT szilardkiss intraocularneutralizingantibodiesagainstafliberceptinpatientswithagerelatedmaculardegeneration |